Study shows non-hallucinogenic cannabinoids are effective anti-cancer drugs

New research from St George's, University of London has shown that the non-hallucinogenic components of cannabis could act as effective anti-cancer agents.

Study shows non-hallucinogenic cannabinoids are effective anti-cancer drugs

14 October 2013

New research has shown that the non-hallucinogenic components of cannabis could act as effective anti-cancer agents.

The anti-cancer properties of tetrahydrocannabinol (THC), the primary hallucinogenic component of cannabis, has been recognised for many years, but research into similar cannabis-derived compounds, known as cannabinoids, has been limited.

The study was carried out by a team at St George’s, University of London. It has been published in the journal Anticancer Research.

The team, led by Dr Wai Liu and colleagues carried out laboratory investigations using a number of cannabinoids, either alone or in combination with each other, to measure their anti-cancer actions in relation to leukaemia.

Of six cannabinoids studied, each demonstrated anti-cancer properties as effective as those seen in THC. Importantly, they had an increased effect on cancer cells when combined with each other.

Dr Liu said: “This study is a critical step in unpicking the mysteries of cannabis as a source of medicine. The cannabinoids examined have minimal, if any, hallucinogenic side effects, and their properties as anti-cancer agents are promising.

“These agents are able to interfere with the development of cancerous cells, stopping them in their tracks and preventing them from growing. In some cases, by using specific dosage patterns, they can destroy cancer cells on their own.

“Used in combination with existing treatment, we could discover some highly effective strategies for tackling cancer. Significantly, these compounds are inexpensive to produce and making better use of their unique properties could result in much more cost effective anti-cancer drugs in future.”

This latest research is part of a growing portfolio of studies into the medicinal properties of cannabis by the research team at St George’s. The next step will be to examine in the laboratory these compounds in combination with existing anti-cancer treatments and study treatment schedules to identify strategies that will maximise their efficacy.

The study examined two forms of cannabidiol (CBD), two forms of cannabigerol (CBG) and two forms of cannabigevarin (CBGV). These represent the most common cannabinoids found in the cannabis plant apart from THC.

Ends

Notes to Editors

For more information or interviews, contact St George’s, University of London Communications on 0208 725 1139 or at media@sgul.ac.uk.

Cannabis, also known as marijuana, is a plant from Central Asia that is grown in many parts of the world today. It is a controlled substance in the UK and is most commonly known as a recreational drug.

Cannabinoids are active chemicals in cannabis. They are also known more specifically as phytocannabinoids. There are 85 known cannabinoids in the cannabis plant. The main active cannabinoid in Cannabis is delta-9-tetrahydrocannabinol (THC).

The cannabis plant is known for its medicinal properties and has been used to relieve symptoms associated with cancer, HIV/AIDS, multiple sclerosis, anorexia, anxiety, depression, and numerous other illnesses and conditions.

Read the full research paper in the journal Anticancer Research http://ar.iiarjournals.org/content/33/10/4373.abstract


 

 

News

100 years on - The part ethics played for army doctors in World War One

The First World War started a century ago. Many medics and doctors were involved in the fighting which left a staggering 16 million people dead including 18 doctors who trained at St George's.

Experts to combat the potential ‘health catastrophe’ of deadly tuberculosis among people with diabetes

New research aims to estimate the benefits of different ways to carry out screening both patients with tuberculosis (TB) for diabetes and the other way around in parts of the world where both diseases are common.

New research finds a way to predict which HIV patients will respond better to future therapeutic vaccine

A new study suggests that HIV patients with a higher level of a particular biomarker, or a measurable indicator found in the blood, may respond more favourably to an experimental immune activating vaccine.

More news…